AtriCure (NASDAQ:ATRC) Cut to Hold at Zacks Research
Zacks Research downgraded AtriCure (ATRC) to "hold" from "strong-buy" despite the company beating Q4 EPS expectations with 13.1% year-over-year revenue growth. The stock currently holds a "Moderate Buy" consensus rating among analysts with an average price target of $48.43, but faces concerns over negative net margin and P/E, and projected negative EPS for the current year. Insider selling has also been noted, with 15,166 shares offloaded in the past three months.
AtriCure, Inc. SEC 10-K Report
AtriCure, Inc. has released its 2025 Form 10-K report, showcasing significant financial improvements and strategic advancements in a competitive industry. The company reported increased revenue, improved gross profit, and a reduced net loss, driven by growth in its open ablation, appendage management, and pain management product lines. AtriCure is also focused on product innovation, including new launches and the development of a novel dual energy platform, while navigating challenges such as market competition, regulatory compliance, and supply chain risks.
AtriCure (ATRC) Turns Q4 Profit And Tests Bullish Earnings Growth Narratives
AtriCure (ATRC) posted a Q4 2025 profit with revenue of US$140.5 million and basic EPS of US$0.04, marking a shift from previous losses. Despite this quarterly improvement, the company remains loss-making on a trailing twelve-month basis, with a basic EPS of US$0.24. This mixed financial picture creates tension between bullish forecasts, which predict significant earnings growth and profitability within three years, and a cautious narrative highlighting the current losses, significant insider selling, and a share price far above its discounted cash flow fair value.
Needham reiterates Buy on AtriCure stock, keeps $45 target By Investing.com
Needham has reiterated a Buy rating and a $45 price target for AtriCure Inc. (NASDAQ:ATRC) following the company's Q4 results, which saw revenue align with pre-announcements and exceed EBITDA and EPS estimates. Despite a slowdown in revenue growth and new competition, the company maintained its revenue and adjusted EBITDA guidance for 2026 and provided above-consensus EPS guidance. However, Oppenheimer downgraded AtriCure to Perform due to competitive concerns, while Citizens adjusted its price target to $52.00, suggesting mixed analyst sentiment.
AtriCure, Inc. (NASDAQ:ATRC) Q4 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC) reported exceptional Q4 and full-year 2025 results, exceeding earnings expectations with a reported EPS of $0.04 against an expected $-0.04. The company achieved $534 million in total revenue for 2025, marking 15% growth over 2024, driven by new product launches and increased adoption of therapies. AtriCure reiterated its 2026 revenue growth guidance of 12% to 14% and discussed strategic initiatives including ongoing clinical trials (LeAAPS and BoxX-NoAF) and advancements in product development, such as the dual energy EnCompass Clamp.
AtriCure Delivers 15% Revenue Growth In FY25, Projects 12-14% Growth In FY26
AtriCure, Inc. (ATRC) announced strong financial results for the fourth quarter and full-year 2025, with adjusted net income of $2.75 million in Q4 and a narrowed adjusted net loss for the full year. Total revenue for FY25 increased by nearly 15% to $534.53 million. The company provided a positive outlook for 2026, projecting revenue growth of 12% to 14%, with expected full-year revenue between $600 million and $610 million, along with positive net income and continued positive cash generation.
BTIG Research Reaffirms "Buy" Rating for AtriCure (NASDAQ:ATRC)
BTIG Research has reiterated a "Buy" rating for AtriCure (NASDAQ:ATRC) with a $54 price target, suggesting a 63.79% upside. This follows AtriCure's strong performance in Q4, where it surpassed EPS expectations and achieved 13.1% revenue growth. Despite this positive outlook and strong institutional investment, the company remains unprofitable on a GAAP basis, with analysts forecasting negative full-year EPS, indicating a key valuation risk for investors.
AtriCure (ATRC): BTIG Reiterates Buy Rating and $54 PT | ATRC St
BTIG has reiterated a Buy rating for AtriCure (ATRC) with a price target of $54. This decision aligns with a positive trend of analyst ratings for ATRC, including recent Buy or Overweight ratings from Needham, JP Morgan, and Canaccord Genuity. Analysts collectively project an average target price of $53.38, implying a 61.89% upside from the current price, further supported by GuruFocus' estimated GF Value suggesting a 45.34% upside.
AtriCure posts Q4 beats on 13% growth, analysts label it 'undervalued' despite rising competition
AtriCure (Nasdaq: ATRC) reported strong fourth-quarter results, exceeding analyst expectations with 13.1% sales growth and significant profit. Shares rose following the announcement, and analysts at BTIG maintained a "buy" rating, considering the company "undervalued" despite emerging competition in the atrial fibrillation treatment market. AtriCure remains focused on durable growth, margin expansion, and advancing strategic priorities to maintain its leadership.
Citizens lowers AtriCure stock price target on valuation adjustment
Citizens has lowered its price target for AtriCure Inc. (NASDAQ:ATRC) from $60.00 to $52.00, while maintaining a Market Outperform rating. The adjustment reflects a new 3x-4x EV/revenue multiple, down from approximately 5x, aligning with peer valuations. Despite the price target cut, Citizens remains bullish on AtriCure's potential for revenue growth and improved profitability, especially following the company's strong Q4 2025 results which exceeded analyst expectations.
Why AtriCure (ATRC) Is Down 12.9% After Issuing 2026 Profitability Guidance And Revenue Outlook
AtriCure (ATRC) stock fell 12.9% after releasing its Q4 and full-year 2025 results and providing 2026 guidance. The company reported a swing to net income in Q4 2025 and projected $600-610 million in revenue with positive net income for 2026. This guidance, while supporting a path to profitability, also highlights ongoing risks from competitive pressures in pulsed field ablation and international pricing.
AtriCure reports surprise Q4 profit on strong worldwide revenue growth
AtriCure (Nasdaq: ATRC) reported a surprising Q4 profit, with worldwide revenue growing 13.1% to $140.5 million, exceeding analyst expectations. The medical device maker's shares rose 6.4% on the news, demonstrating a recovery despite broader pressures in the medical technology sector. The company also provided 2026 revenue guidance of $600 million to $610 million, indicating continued growth expectations.
AtriCure: Fourth Quarter Earnings Overview
AtriCure Inc. reported a net profit of $1.8 million for the fourth quarter, with earnings of 4 cents per share, surpassing analyst expectations. The medical device manufacturer generated $140.5 million in revenue during the quarter. For the full year, the company narrowed its net loss to $11.4 million on revenues of $534.5 million and projects future earnings between 9 and 15 cents per share, with revenue between $600 million and $610 million.
AtriCure: Fourth Quarter Earnings Overview
AtriCure Inc. reported a net profit of $1.8 million for the fourth quarter, or 4 cents per share, surpassing analyst expectations for a loss. The medical device manufacturer generated $140.5 million in revenue for the quarter and narrowed its full-year net loss to $11.4 million with annual revenue of $534.5 million. Despite these positive earnings, the company's stock price has seen a 17% decline since the start of the year and a 19% decrease over the past twelve months.
Earnings Flash (ATRC) AtriCure, Inc. Reports Q4 Revenue $140.5M, vs. FactSet Est of $139.7M
AtriCure, Inc. (ATRC) reported fourth-quarter revenue of $140.5 million, surpassing the FactSet estimate of $139.7 million. The company's Q4 also saw a swing to profit and it issued guidance for the upcoming period. This positive financial performance was announced on February 17, 2026.
AtriCure Reports Fourth Quarter and Full Year 2025 Financial Results
AtriCure, Inc. announced its financial results for the fourth quarter and full year 2025, showing significant revenue growth driven by new product adoption and strategic initiatives. The company reported $140.5 million in revenue for Q4 2025 and $534.5 million for the full year, with positive adjusted EBITDA for both periods. AtriCure projects continued growth for 2026, with anticipated revenues between $600 million and $610 million and further improvement in profitability.
AtriCure: Q4 Earnings Snapshot
AtriCure Inc. reported a net income of $1.8 million in the fourth quarter, translating to 4 cents per share, surpassing Wall Street expectations for a loss. The medical device maker posted quarterly revenue of $140.5 million and expects full-year earnings between 9 cents and 15 cents per share on revenue of $600 million to $610 million. Despite these positive results, AtriCure shares have decreased 17% since the start of the year and 19% over the past 12 months.
Needham reiterates Buy rating on AtriCure stock amid competition By Investing.com
Needham has reiterated a Buy rating and a $45.00 price target on AtriCure Inc. (NASDAQ: ATRC) despite upcoming competition in the left atrial appendage closure (LAAC) market from Edwards Lifesciences. The firm highlights AtriCure's strong revenue growth and financial health, suggesting its established market position and specialized tools will help maintain growth even with new entrants. Other analysts have varied perspectives, with some downgrades due to competitive concerns, while others maintain optimistic ratings based on clinical trial potential.
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of "Moderate Buy" by Analysts
AtriCure, Inc. (NASDAQ:ATRC) has received a consensus "Moderate Buy" rating from nine analysts, with an average one-year target price of $52.83. The stock opened at $31.80, down 3.3%, with a market cap of $1.58 billion, and has a 52-week range of $28.29 to $43.18. Recent insider sales amount to $676,378, while institutional investors hold approximately 99.11% of the shares.
Needham reiterates Buy rating on AtriCure stock amid competition
Needham has reaffirmed its Buy rating and a $45.00 price target for AtriCure Inc. (NASDAQ:ATRC), despite impending competition from Edwards Lifesciences in the left atrial appendage closure (LAAC) market. The firm anticipates AtriCure will maintain low-teens overall revenue growth, citing the company's past resilience to competition and potential disadvantages for Edwards Lifesciences in the surgical LAAC market. AtriCure recently reported a 13% increase in Q4 2025 revenue, and analysts hold varied perspectives on its future amid competitive pressures.
AtriCure's (ATRC) "Buy" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC has reaffirmed its "Buy" rating for AtriCure (NASDAQ:ATRC) with a $45 price target, suggesting a potential upside of 36.78% from its previous close. Other analysts have also weighed in, resulting in a consensus "Moderate Buy" rating and a target price of $51.11 for the medical device company. Insider selling of 18,166 shares worth $676,378 has been reported, while institutional investors and hedge funds own 99.11% of the stock.
Needham reiterates Buy rating on AtriCure stock amid competition
Needham has reiterated a Buy rating and a $45.00 price target for AtriCure Inc. (NASDAQ:ATRC), despite anticipated competition in the left atrial appendage closure market from Edwards Lifesciences. The firm highlights AtriCure's resilience to past competition and its strong revenue growth, expecting it to maintain low-teens overall revenue growth. AtriCure also reported a 13% revenue increase in Q4 2025, though analyst opinions are mixed regarding future performance amid competitive pressures.
AtriCure stock maintains Market Outperform rating at Citizens despite Edwards competition
Citizens has maintained its "Market Outperform" rating and a $60.00 price target for AtriCure Inc. (NASDAQ:ATRC), even as competitor Edwards Lifesciences prepares to introduce a new surgical LAAC technology. Despite a 15% stock drop following Edwards' announcement, AtriCure demonstrates strong fundamentals with a 3.87 current ratio and 15.8% revenue growth. Analysts have mixed views, with JPMorgan downgrading to Neutral due to competition, while Piper Sandler maintains an Overweight rating, citing the potential of AtriCure's BoxX-NoAF clinical trial.
(ATRC) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Atricure Inc. (NASDAQ: ATRC) based on AI models, highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes the current price dynamics and execution-aware positioning for ATRC.
JPMorgan downgrades AtriCure stock rating to Neutral on Edwards competition
JPMorgan has downgraded AtriCure Inc. (NASDAQ:ATRC) from Overweight to Neutral and reduced its price target due to upcoming competition from Edwards Lifesciences in the surgical left atrial appendage closure market. Although AtriCure has previously shown resilience to new market entrants, JPMorgan is concerned about Edwards' significant presence in cardiac surgery, which aligns closely with AtriCure's "Open" business segment. Investors are awaiting further details on Edwards' product and AtriCure's upcoming earnings report.
AtriCure (ATRC) Shares Fall 15% Following JPMorgan Downgrade
AtriCure (ATRC) experienced a 15% drop in share price after JPMorgan downgraded the stock from Overweight to Neutral, reducing its price target from $48 to $36. This downgrade was largely due to anticipated competitive pressure from Edwards Lifesciences (EW), which plans to introduce a competing surgical product. While AtriCure demonstrates strong financial health with robust revenue growth and a solid balance sheet, it faces profitability challenges and increased market volatility.
AtriCure (NASDAQ:ATRC) Shares Gap Down After Analyst Downgrade
AtriCure (NASDAQ:ATRC) experienced a significant gap down in its share price after JPMorgan Chase & Co. downgraded the stock from "overweight" to "neutral" and reduced its price target to $36. Despite the downgrade, the current analyst consensus remains a "Moderate Buy" with a target price of $51.11. The article also highlights recent insider selling activity, with 18,166 shares sold in the past 90 days, while institutional ownership stands at approximately 99.11%.
JPMorgan downgrades AtriCure stock rating to Neutral on Edwards competition
JPMorgan downgraded AtriCure Inc. (NASDAQ:ATRC) from Overweight to Neutral and reduced its price target to $36.00 due to anticipated competition from Edwards Lifesciences, which plans to launch a competing surgical left atrial appendage closure product. Although AtriCure has previously shown resilience against competition, JPMorgan is concerned about Edwards' significant presence in the cardiac surgery market, which could pressure AtriCure shares in the near term. This comes as AtriCure recently reported a 13% revenue increase for Q4 2025, and Piper Sandler reiterated an Overweight rating, highlighting the potential impact of the BoxX-NoAF clinical trial.
AtriCure (ATRC) Projected to Post Earnings on Tuesday
AtriCure (ATRC) is expected to announce its Q4 2025 earnings after market close on Tuesday, February 17th, with analysts forecasting a loss of ($0.04) per share and revenue of $140.5 million. The stock currently has a "Moderate Buy" rating with a consensus price target of $52.44, though insider selling has increased recently. Institutional investors hold a significant portion of the company's shares.
AtriCure stock maintains Overweight rating at Piper Sandler on BoxX-NoAF potential
Piper Sandler has reiterated an Overweight rating and a $50.00 price target for AtriCure Inc. (NASDAQ:ATRC), based on the significant potential of its BoxX-NoAF clinical trial. The firm projects the trial will likely yield positive results, leading to a potential label approval around 2028, with the ability to accelerate revenue growth by at least 250 basis points and generate $300-$400 million in incremental sales. AtriCure also reported a 13% increase in revenue for Q4 2025, reaching $140.5 million.
AtriCure stock maintains Overweight rating at Piper Sandler on BoxX-NoAF potential
Piper Sandler has reiterated an Overweight rating and a $50.00 price target for AtriCure Inc. (NASDAQ:ATRC), emphasizing the significant potential of its BoxX-NoAF clinical trial. The trial, which has garnered minimal investor attention, is expected to yield positive results and could accelerate AtriCure's revenue growth, potentially adding $300-$400 million in incremental sales by targeting a projected $1.8 billion market. Additionally, AtriCure recently reported a 13% increase in Q4 2025 revenue, reaching $140.5 million, demonstrating solid financial performance.
(ATRC) as a Liquidity Pulse for Institutional Tactics
This article provides a detailed analysis of Atricure Inc. (NASDAQ: ATRC) based on AI-generated signals for institutional trading. It highlights weak near and mid-term sentiment, a neutral long-term outlook, and identifies resistance being tested. The analysis offers specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, alongside multi-timeframe signal analysis.
Red-hot medical device firm gets big JobsOhio grant for $45M expansion
AtriCure, a rapidly growing medical device company in the Cincinnati region, has secured a $6 million JobsOhio grant for a $45 million expansion project in Mason, set to create 400 new jobs. This grant is the largest JobsOhio award to a Southwest Ohio project in 2025. The expansion includes a 120,000-square-foot facility for laboratory, R&D, office, and advanced manufacturing operations.
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
AtriCure, Inc. announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. The company will also host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested parties are encouraged to register online for the webcast.
The Zacks Analyst Blog Highlights AtriCure, REV Group, Oceaneering International and Analog Devices
This Zacks Analyst Blog identifies four "high efficiency" stocks—AtriCure (ATRC), REV Group (REVG), Oceaneering International (OII), and Analog Devices (ADI)—poised for superior returns. The selection process involved screening companies based on key efficiency ratios such as receivables turnover, asset utilization, inventory turnover, and operating margin, in addition to a Zacks Rank #1 (Strong Buy). These efficiency measures help gauge a company's ability to convert input into output and manage expenses effectively.
AtriCure (ATRC) Is Up 5.1% After Raising 2026 Guidance And Refinancing Credit Facility - Has The Bull Case Changed?
AtriCure (ATRC) saw a 5.1% stock increase after raising its 2026 revenue guidance to US$600-$610 million and refinancing its credit facility with more favorable terms. This move signals management's confidence in growth plans and improves liquidity, though core risks such as unprofitability and insider selling remain. The company's investment narrative still hinges on the ability of its specialized cardiac and pain-management technologies to become a larger, profitable business.
Left Atrial Appendage Devices Market Insights | Innovations, Investments, and Regional Opportunities | Top Companies are AtriCure, Abbott, Biosense Webster
The Left Atrial Appendage Devices Market, valued at $490 million in 2021, is projected to reach $X million by 2031, growing at a CAGR of 20.2%. Key players like Boston Scientific, AtriCure, and Abbott are driving innovations and strategic acquisitions, with recent developments including new product launches and clinical trials in both the United States and Japan. The market report provides insights into product, procedure, and end-user segmentation, along with regional analysis and growth forecasts.
SG Americas Securities LLC Has $824,000 Position in AtriCure, Inc. $ATRC
SG Americas Securities LLC significantly reduced its stake in AtriCure, Inc. (NASDAQ:ATRC) by 53.5%, selling over 26,000 shares, but still holds 23,388 shares valued at $824,000. Despite the reduction by SG Americas, institutional investors collectively own 99.11% of AtriCure, and the company recently outperformed earnings estimates though it remains unprofitable. Analysts maintain a "Moderate Buy" rating with an average target price of $52.44, while insiders have been net sellers.
(ATRC) Risk Channels and Responsive Allocation
This article analyzes Atricure Inc. (NASDAQ: ATRC), highlighting divergent sentiment across different time horizons and indicating choppy conditions. It presents an exceptional 43.8:1 risk-reward setup targeting a 13.0% gain. The piece also outlines three distinct AI-generated trading strategies tailored for different risk profiles and holding periods, including position, momentum breakout, and risk hedging strategies.
A Look At AtriCure (ATRC) Valuation After Earnings Update Signals Profitability Shift
AtriCure (ATRC) recently released a preliminary earnings update, signaling a shift towards full-year profitability in 2026, supported by double-digit revenue growth guidance and stronger adjusted EBITDA. Despite positive recent momentum, long-term shareholder returns remain modest. The company's valuation is currently debated, with a popular narrative suggesting it is 21.9% undervalued at $39.06 against a fair value of $50, while a DCF model estimates fair value at a much lower $0.77.
AtriCure Inc (ATRC) Shares Up 8.49% on Jan 15
AtriCure Inc (ATRC) saw its shares rise 8.49% to $40.51 on January 15, placing it 6.18% below its 52-week high. Wall Street analysts forecast an average target price of $52.78, suggesting a 30.28% upside, and an "Outperform" consensus rating. GuruFocus estimates a GF Value of $47.32, indicating a 16.81% upside for the stock.
Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?
AtriCure (ATRC) recently announced preliminary 2025 results and positive adjusted EBITDA projections for 2026, alongside new product launches and an extended credit facility. This development modestly strengthens its investment narrative, providing financial flexibility and supporting commercial and clinical efforts. However, the company still faces risks from competitive technologies like pulsed field ablation, which could impact long-term performance.
ATRC: Innovation and clinical evidence drive growth in AFib and pain management, with strong financial results
AtriCure, Inc. (ATRC) is addressing a $10 billion market opportunity in AFib and pain management through innovation, with a strong global presence and rapid growth. The company's expansion is driven by clinical trials and new products, while its financial performance has exceeded guidance. Ongoing innovation helps AtriCure maintain a competitive edge.
AtriCure (NASDAQ:ATRC) Shares Down 7.6% - Time to Sell?
AtriCure (NASDAQ: ATRC) shares dropped 7.6% on Monday to approximately $38.30 on unusually low trading volume. Despite the decline, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $52.44, and the company recently beat quarterly EPS and revenue estimates. While AtriCure remains unprofitable, it exhibits strong liquidity and low leverage, though insiders have sold a notable number of shares in the past 90 days.
AtriCure Reports Strong Preliminary 2025 Revenue Growth
AtriCure (ATRC) reported strong preliminary unaudited Q4 2025 revenue of $140.5 million, up 13% year-over-year, and full-year 2025 revenue of $534.5 million, an increase of 15%. The company also amended its credit facility, lowering interest rates and removing a minimum utilization covenant, enhancing its financial flexibility. An analyst rating from TipRanks' AI Analyst, Spark, rates ATRC as Outperform, citing strong financial performance despite valuation concerns.
AtriCure reports 13% revenue growth in Q4 2025, provides 2026 outlook
AtriCure, Inc. announced preliminary Q4 2025 revenue of $140.5 million, marking a 13% increase, and a full-year revenue of $534.5 million, up 15% from 2024. The company projects 2026 revenue to be between $600 million and $610 million, anticipating positive adjusted EBITDA and net income. This growth is driven by strong performance in Pain Management, Open Ablation, and Open AtriClip devices, with analysts holding a bullish outlook for the company.
AtriCure reports 13% revenue growth in Q4 2025, provides 2026 outlook
AtriCure, Inc. (NASDAQ:ATRC) announced a 13% revenue growth for Q4 2025, reaching $140.5 million, and a 15% increase for the full year to $534.5 million. The company projects 2026 revenue to be between $600 million and $610 million, anticipating positive adjusted EBITDA and net income for the year. This positive outlook is supported by strong performance in Pain Management, Open Ablation, and Open AtriClip devices, and aligns with bullish analyst sentiment.
AtriCure's preliminary Q4 revenue rises 13%, slightly beats estimates
AtriCure (ATRC) announced a preliminary 13% increase in its fourth-quarter revenue, which slightly surpassed estimates. The news item is a headline-only report from Reuters with no further textual details provided in the article.
Afib surgery device maker AtriCure expects to turn a profit in 2026
AtriCure (ATRC) announced preliminary financial results for the fourth quarter and full year 2025, exceeding revenue expectations. The company projects 2026 revenue between $600 million and $610 million, with positive adjusted EBITDA and anticipates achieving full-year net income in 2026. This outlook reflects strong growth in its surgical treatments for atrial fibrillation and related conditions.
AtriCure Reports Strong Preliminary 2025 Revenue Growth
AtriCure (ATRC) has reported strong preliminary unaudited revenue for the fourth quarter and full-year 2025, showing double-digit growth driven by demand in pain management, open ablation, and AtriClip devices. The company also improved its asset-based revolving credit facility, enhancing liquidity and financial flexibility, and anticipates improving profitability with a solid balance sheet. Analysts currently rate ATRC stock as a Buy with a $48.00 price target.
